Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00080041
Status:
COMPLETED
Last Update Posted:
2007-05-15
First Post:
2004-03-22
Brief Title:
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
Sponsor:
Pharmacyclics LLC
Organization:
Pharmacyclics LLC
Study Overview
Official Title:
Phase I Trial of Motexafin Gadolinium MGd and Docetaxel Administered at 3-Week Intervals for Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate the safety toxicities and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors Secondly tumor response to the combined treatment will be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None